Reflux, Migraines, IBS, Brain Fog… What If It’s All Your Mast Cells?
1 hr 9 minAudio
Unexplained symptoms across multiple body systems, normal labs, and a doctor who says you look fine? Mast cell activation syndrome (MCAS) may be part of the answer, and most clinicians were never taught to look for it. In this episode I sit down with gastroenterologist and researcher Dr. Leonard Weinstock, co-author of the global Consensus-2 diagnostic criteria for MCAS and the 2026 follow-up paper Progress in Mast Cell Activation Syndrome. We cover why one of the most common immune disorders is still missing from medical textbooks, and why so many patients are dismissed before they’re ever tested. In this episode: Where MCAS came from. How Dr. Molderings’ work nearly 20 years ago separated a non-malignant mast cell disorder from systemic mastocytosis and mast cell leukemia. The two sets of diagnostic criteria. Consensus-1 depends on anaphylaxis and a tryptase spike drawn within hours of a flare. Consensus-2 looks at symptoms in two or more body systems, a broader set of mediators, and response to treatment. That difference explains why prevalence estimates run from about 4% to 17%. Why testing misses people. A test drawn on a “good day” can be falsely negative 30-40% of the time. Mild cases. Some patients have only stubborn reflux and seasonal allergies, which is why “you don’t look sick enough” fails them. Triggers. Perfume, smoke, chemical odors, metal implants, and infections like COVID or mono, and how a single event can permanently lower someone’s baseline. Long COVID and alpha-gal. Both can look nearly identical to MCAS. Gelatin capsules and magnesium stearate in supplements can quietly keep a reaction going. The treatment ladder. H1/H2 blockers, why fillers in a pill can cause a reaction that has nothing to do with the drug itself, vitamin C and D, quercetin or luteolin, and microdosed low-dose naltrexone (LDN). Low-dose GLP-1 therapy. Its anti-inflammatory effects, including a patient who had been bedbound for 12 years and recovered. The POTS connection. Mast cells live along the sympathetic nervous system, and about 60% of POTS patients improve with mast cell treatment. Concussion and puberty. Why head injuries and hormonal changes can switch MCAS on, especially in young female athletes. Finding care, and why “practitioners serve human needs first, science second.” Resources: Triad Library: triadlibrary.org Understanding Stealth Syndromes, a 59-minute documentary on YouTube that’s worth sharing with family who don’t understand what you’re going through: Watch here This episode is for educational purposes and isn’t medical advice. Talk with a qualified provider about your own care.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00If you have a variety of unexplained symptoms and are struggling to get answers, then mast cell activation syndrome is something you should know about. I'm joined by a special guest, Dr. Weinstock. He's a gastroneurologist and a researcher who's been involved in the publication of many articles, which includes the diagnosis of mast cell activation syndrome, a global consensus two, which was published in 2020, and more recently a follow-up article published in 2026 called Progress in Mast Cell Activation Syndrome. Dr. Weinstock, thank you so much for joining me.
SPEAKER_02Thank you so much for asking me. Um, so many people are looking towards the answers, and so many people have started doing the digging and come to see me with do I have MCAS?
SPEAKER_00Correct. And that question's being asked a lot more recently. If I look back on my textbooks for nurse practitioner school and stuff like that, it's not even mentioned, it's not referenced at all. And patients are coming in, like you said, they're asking you about it, they're asking me about it, which begs the question when was MCAS even discovered?
SPEAKER_02In 2007. Uh, Dr. Mulrings uh had a case series of patients who had um multisystemic problems. He developed a checklist of symptoms uh leading towards diagnostic symptoms, and then this is the most important thing, he looked at the mast cells themselves and found uh mutations on the mast cell controller gene.
SPEAKER_02And that leads to mast cell activation syndrome.
SPEAKER_00Okay, so it's been basically 20 years since the first thing published, and then we know there's a big delay from the time anything's published till it actually gets talked about in a meaningful way.
SPEAKER_02Absolutely. Um, and you know, there's there was interest before he diagnoses, um, you know, because they there's this disease called systemic massocytosis, which has some allergic phenomenon with it. And uh if you look at that uh but don't know about um the benign side of things, so to speak, a non-malignant mast cell disease like systemic massocytosis, then you you're not really sure what could be going on until Dr.
SPEAKER_02Muldering's publication came out in 2007. And then there were case series uh that led towards more recognition of the disease over the next, oh, let's say 10 years.
SPEAKER_00Okay. So what is mast cell activation syndrome? You know, because you said it's you got the benign side here, and then on the other side, you have more of a pathologic, malignant side.
SPEAKER_02Right. So if you look at mast cell activation disease, that has three diseases underneath that category name. You have systemic massocytosis, which people have known about for years. It's a malignant disease, but it can be indolent, namely gradually taking a person down, but they live with it for a long time. And then they have mast cell activation syndromes, and there are different syndromes, one with markers for um the mutations and one without.
SPEAKER_02And then there is mast cell leukemia, and so that's a very rare but highly malignant leukemia. So um, in terms of looking at the syndrome complex, you know, you have those three diseases, and they can resemble each other because they're the mast cell is spitting out chemicals like the other elements and the other disorders under the category of the MCAD mast cell activation disease.
SPEAKER_00And then there's been a lot of you know progress, we'll we'll call it semi-recently, as it is really new, and there's different, there's really two consensus, you know, there was consensus one, and then you're involved in consensus two. Let's just walk through what each one of those are. Um, because depending on where someone's at in the world, you know, or even in the United States, some providers are if they adhere to any of this, you know, they're adhering to one versus the other.
SPEAKER_02Right. Well, consensus two is described before consensus one, um, and that's uh by Dr. Molderings and Dr. Afrin together. And so they describe the basics of consensus two, which I can describe now, uh, especially since we again had that nice article in 2006 about consensus two. It's symptomatology characteristic for mast cell disorders.
SPEAKER_02That's the uh and two or more of those symptoms and systems will um be the first part of the diagnosis for the criteria. The second criteria are one or more of the minor criteria, and I'll go over that in a minute, and then finally the uh fact that you have to rule out other diseases that can look just like it.
SPEAKER_02So, in terms of the minor criteria, you have certain genes that can be abnormal, but those are really uh sought out in the research lab. You can have um the biopsy showing more than 20 mast cells per high power field, and you can have mast cell chemicals, which are typical for mass cells, and are more expansive than what we'll talk about with consensus one.
SPEAKER_02And then finally, and this is very similar to consensus one, mass cell directed therapy works to help people feel better. So that's consensus two. Consensus one, which was developed mainly by the allergists abroad and um in the University of Michigan and Massachusetts General, is multiple symptoms, which usually should include um anaphylaxis, which is a life-threatening disorder, and tryptase elevation during an attack of two or more plus two percent, twenty percent, pardon pardon me.
SPEAKER_02And that's the way it was. Uh, and then earlier on it said if your urine tests were abnormal as well, that would be diagnostic. And then finally, again, mast cell therapy helps get a person feeling better. So the differences are they want consensus one wants to see that a patient's had anaphylaxis, which consensus two group does not require, and we find it uncommonly.
SPEAKER_02Both groups are such that you have uh success with treatment, at least partial, anyway. And then finally, you drill down on the um chemicals, the mast cell mediators, and for um our group, it's any of the mediators, and for consensus one, it's generally tryptase level that goes up during an attack.
SPEAKER_02And if you can't, and now it's saying if you can't get to that lab done, you could then do urine testing, and if those are elevated, then that's clinically significant.
SPEAKER_00Yeah, I mean, and one of the challenges with consensus one, even if everything was perfect, it's you know, if someone's in a bad enough flare with tryptase, it's like, how do you even get someone in within a four-hour window? That's very hard. You'd have to require emergency rooms to be testing for it, and that's not going to happen. And this brings us up to you know how this impacts the amount of the population who has it, because in you know, even in the update, you know, y'all rightly acknowledge like, okay, consensus one may be too narrow, and then the criticism for consensus two is it may be too broad.
SPEAKER_02Exactly.
SPEAKER_00And you know, what's kind of the difference, right? Consensus one, probably X amount of the population has it versus consensus two, it's what percentage?
SPEAKER_02Well, that's a good question. Um, so in Dr. Muldering's 2013 paper, he looked at the prevalence of mast cell activation syndrome in Germany and found that 17% of the population had MCAS, and 70% of those patients had relatives who could be diagnosed with MCAS. Going back to what you just said beautifully, is that how do you get a person in uh to measure their tryptase?
SPEAKER_02Well, you can do it in your own office. Patient may be ill, but you need to do it when they're really symptomatic. And when I get a patient in, I usually will ask the patient, you know, are they having a good day or a bad day? And many times they're not having any kind of day, but generally they're having something wrong with them, whether it's fatigue and fog. And so I'll offer them the testing, basic testing.
SPEAKER_02But if um, pardon me. Um anyway, uh, the if they have the um illness active, I will check them out with the test. If they're not symptomatic, I'll wait till they're they are and have them come back, maybe after heat exposure or um exercise or eating some histamine food to a mild degree, could get them active enough.
SPEAKER_02So I will do that because otherwise it's about um 30 to 40 percent are falsely negative in terms of the mast cell uh mediators. Now, the other thing to think about is the fact that many of the allergists are not familiar with the census one criteria, they'll get a baseline uh tryptase level, and if it's normal, they say to the patient, well, you can't have uh MCAS.
SPEAKER_02So I did give you the statistic of 17%, which is an amazingly high statistic. But if you look at the syndromes as part of that, you've got things like irritable bowel syndrome, which occurs in 15% of the population. You have migraines, it's certainly in the 5% range, interstitial cystitis is common, chronic urticaria relatively common. So this um these syndromes, if you will, uh, are things that clearly are things that MCAS patients have.
SPEAKER_02So if you can put it into one lump sum, that will allow a diagnosis in many of the patients out there. And then finally, there is one paper that looked at 700 patients who came to allergies and um using the consensus one criteria. 4% of the 700 patients could be diagnosed with consensus one, which is not a lot, but a lot of them are again not worked up the full way, they're not uh tested for all the mediators, and so um it's a uh dilemma for patients.
SPEAKER_00Yeah, and that's a big difference, and we'll we'll come back to one of my takeaways from consensus two at the end, but you know, that's a big difference when you're looking at it, and I'm glad you also point out, you know, under MCAS or the mast cell related disorders, you know, IBS, migraines, and everything, because one of the things I jotted down was anytime we look at these just full spectrums, because I kind of view it as a spectrum, I view POTS as a spectrum, you know, not every pot is the same, not every MCAS is the same, the the impact on someone's life.
SPEAKER_00And it's very easy for people to say, like, ooh, I have anaphylaxis, you know, you know, this is severe, or even without anaphylaxis, some people know that they are severe, you know, just the respiratory issues, the cardiovascular manifestation, the neurological, the GI, they just have so many. But with the consensus to diagnostic area, it's just two systems plus symptoms, you know, it's it doesn't have to be wholly systemic.
SPEAKER_00So, what does something look like from a mild side? Like, what are cases that could be walking into a provider's office where they're just thinking, like, you don't look like you've got this? And it happens in pots all the time, too.
SPEAKER_02Okay. Well, first of all, each of the consensus criteria have two or more syndromes or symptoms of involvement, and so it's systems involved. So two or more systems. So if let's say you you had um hives, angioedema, um uh cystic acne, um, that would be like skin dermological uh involvement, and then fatigue, that would be uh, let's say, the constitutional syndrome.
SPEAKER_02That's a possibility, so two or more, um, but that's two systems are involved. Now, the easiest patient I ever had was a 40-year-old man who had refractory uh acid reflux despite being on a proton pump inhibitor. And then he also had seasonal allergies, so pretty severe seasonal allergies. And so I said, Well, could this be MCAS?
SPEAKER_02And um put him on H1 blocker and H2 blocker, and he's done great ever since. He's gotten off the PPI and he's on uh certrazine and um and um tagamed twice a day, and he's doing perfectly well. So um that's the easiest case ever. And then the cases where they have numerous symptoms and you do the moldering's uh symptom score, and they have 35 symptoms, um, they can be very difficult.
SPEAKER_02And part of the reason is that in general, we can say that mast cells um the number of mast cell uh mediators, the chemicals, could be over a thousand in a person. So you have all the potential symptoms. Now, usually it's 200 or less, but that said, if with all those chemicals running around the blood or within tissues, you can have numerous, numerous symptoms.
SPEAKER_00Yeah, and you know, using your example on the acid reflux and allergies, most people would never even consider that. They'd be like, oh, that's not, you know, that that doesn't seem bad enough. And I think that does hurt a lot of patients when we look at providers and the way providers take it, you know, is well, you don't seem bad enough to meet this, so I'm not even gonna test. And I it's why just you know, I'll do a tilt table on anyone who may have pots. I'm like, look, let's just do it. Worst case scenario, I wasted 10 minutes. Um, but I have a lot of people who looking at them, you could argue you look too healthy for this.
SPEAKER_00And so we've got to get through this concept, you know, misconception that unfortunately is harming a lot of people, which once again we're gonna get to later on. One of the things I loved. Um, and going in just a little bit about what you were talking about with all the mediators being released. One of the things that y'all said in the update was many chemical and other foreign material exposures, long thought inactive and inconsequential, are significant triggers, even at low levels in some patients in whom treatment success are limited while trigger exposure continues.
SPEAKER_00Um let's briefly talk about what some of those things may be and about that chronic low-grade inflammatory response or immune response.
SPEAKER_02Right. Um, well, also one last thing we didn't talk about was that the mast cell has 300 receptors. Some are activating and some are deactivating. So why um does somebody have a flare or a trigger? And I looked at the number of triggers. There are 50 or more triggers that are well described both in papers and uh by our experience. So that's tremendous. But as far as odor goes, um one of my patients had 12 and 14-year-old daughter daughters um who would love to slather um perfume on when they went out, but and the mom would have to drive them and would go into flair, and they just couldn't get it between themselves.
SPEAKER_02But I would say um perfume, cigarette, um, chemical odors are the big, big triggers, and many have been that way their whole life in terms of being sensitive to it. And you ask them what happens to you, and they'll say they have nausea, they feel like passing out, some pass out, and um, but nausea and headaches are the most.
SPEAKER_00And so whenever we look at the triggers, um, and let me phrase it this way are we looking at things that people have always had their entire life, or are we also looking at things where, because online, you know, I get people who comment on myself all the time, like I was fine until surgery. I was fine until I have this infection or this exposure. And since that point in time, my system has just been, you know, it's been off. It's chaos.
SPEAKER_02Well, surgery, uh, one concern is if they're allergic to metals and they've been uh given, let's say, um, titanium with nickel or nickel uh nickel alloy. Um, so a foreign body put or mesh, for instance, uh put into your body could be a constant trigger. And so people can step down in terms of their well-being and lack thereof. Uh and then um your other thing to mention is what happens if you get COVID.
SPEAKER_02That can lead to a permanent step down in your health uh andor um permanent um long COVID by itself. And you can't really tell the types um from one another because as we proved um in a paper looking at uh MCAS, untreated MCAS versus controls versus uh long COVID patients, the long COVID patients had the exact same symptoms as did the untreated MCAS patients.
SPEAKER_02So it's very much uh MCAS-like illness, long COVID is. And so what can happen? You can get more mutations uh after, let's say prolonged infectious mononucleosis or long COVID, or the diseases that cause chronic fatigue syndrome.
SPEAKER_00Yeah, and I think that's at least in part is what makes some of this controversial. You know, obviously you've got consensus one versus consensus two. You also have the Hierarchy of evidence that medicine's been taught that they should have. So let's just briefly talk about why it's controversial and maybe this will help those listening understand why they struggle, unfortunately, so much to really to feel understood in regular medicine.
SPEAKER_02Well, first of all, going back to your comment, um, that you don't look ill. Um, because many people don't look ill. But uh that said, many people are having flushing while they come in and they're seen. So that's something. And actually, there's a number of skin um signs that you need to look for in a physical exam, like hemangiomas, the cherry red angiomas on the trunk or uh chest.
SPEAKER_02And then when you see that, you ask the patient during attacks, do those get um inflamed, enlarged, itchy, or burning? Then um patients will also whip out their phone and show me multiple different kinds of rashes, hives, um, quite a number of conditions. We've looked at um this and found 20 different disorders, and there are probably even more, and hoping to publish that article.
SPEAKER_02Um, so in terms of do you look ill or not? That's one really important one. Because if they're not looking ill, then the patients are gaslit.
SPEAKER_00Yeah, and I have a lot of patients who come in and they're like, I almost have to go in there and put on a face because if I don't, I just get ignored, which is like you said, it's sad that they're being gaslit because you know, there's a lot of them who they're just their personality is, they don't want to look sick, you know, so they do as much as they can to look good, but then when they go look good, they're then being gaslit and they're not getting you know the help they need. And unfortunately, that's a growing it's always been an issue, really, in in medicine.
SPEAKER_00You know, I remember working on well, I was going through nurse practitioner school, I worked on a neurology unit at a teaching hospital, and the residents would make fun of the patients who came in who thought they had mold or Lyme-related issues. And it's just like look, I get it. I get it. Like in some areas, this maybe is overly blamed, but then in other areas, this is widely ignored, you know.
SPEAKER_02It depends, you know, where you try it. Uh, if you're in New York State, you know that Lyme disease exists uh in Connecticut, where it really took off. Lyme Connecticut is where it all took off. And now in the Midwest, we're seeing so much uh tick-borne disease with alpha gal. In fact, I saw three on Friday, three patients on Friday. They're all on supplements to try to help them get better, but they weren't getting better. I copied their supplement list, put it into AI, and came up with each of them having five or more supplements that were not kosher for Alpha Gal.
SPEAKER_02So um, yeah, that's really something else. Um, and it is hard for some of the Alpha Gal patients because for them, odor triggers it. Um, and then one of the doctors in my group was an allergist, said that many of the Alpha Gal patients are looking like MCAS patients now.
SPEAKER_00Yeah, and briefly talk about Alpha Gal because just like MCAS was something not really ever talked about previously. Alpha Gal, I mean, I remember hearing about it a decade ago, but it was just super uncommon. And maybe it's just because I'm in this space and this is all I'm seeing now, but I'm hearing it way more than I ever did. So just briefly talk about what Alpha Gal is.
SPEAKER_02Okay, so it is an um allergy to the meat, um, mammalian meat. So that would be cows or beef, uh, pork, bacon, and other pork uh processes, and then you also have um lamb, and you have uh aspects of the beef or cattle that have IgE um and triggers, namely um the hoofs, uh, which gives you gelatin or uh magnesium stearate and other products that they put in capsules and pills, and then um uh milk cheese, and so you can get uh enough mammalian IgE from these uh chemicals and food products that when you consume it, you start getting allergic phenomena, especially GI first, although it may have a 12-hour window where you know you eat uh a piece of steak, and then 12 hours later you're having severe crampy diarrhea, nausea, and vomiting.
SPEAKER_02And then um you can have allergic phenomena, um anaphylaxis, or um let's say hives, immediately or later as well. And now at least uh the uh uh the ER doctors are knowing to ask the question about uh getting a tick bite. Uh part of the problem with alpha gal ticks, they can bite and then fall off. Um, and then that exchange of blood is enough to for the uh alpha gal to put in the um serum into the uh blood, and then you get this allergy.
SPEAKER_02Luckily, want to highlight one of the things you said about yeah, sorry, if you give them uh a number of years where they stay off of consuming meat and meat products, they can uh lower their uh IgE levels and get back to eating meat.
SPEAKER_00Okay. And I do want to highlight one of the things you had said using the example of the supplements, you know, a lot of people are trying to treat stuff naturally, and they may not be aware that the supplement with the gelatin capsule, the magnesium sterate, which is a very common filler, that you know, they'll be like, but I'm responding to everything. It's like, you know, you're probably not reacting to vitamin D. You're probably not reacting to vitamin C and some of the other stuff, but you may be reacting to a filler or what encapsulates it.
SPEAKER_00Um and those are things that really aren't being considered. Now, one of the things we'd said between both consensus one and consensus two is that there is we're gonna call it enough of an agreement that these individuals should have a response to treatment. It looked like consensus two was more open to the idea of like, hey, we still have a lot we don't know, and so maybe even if someone's not responding as we advance, we're gonna get something that they can respond to.
SPEAKER_00But currently, how is MCAS treated?
SPEAKER_02Okay, so um H1, H2 blockers um twice a day uh is the really important one, although um, because of all those receptors, you have to jump ahead and try other things. Now, one thing that Dr. Afrin does is he um will switch around the H1 blocker to find the best one because sometimes one is better than another.
SPEAKER_02Uh, and then there are three total H2 blockers. Problem with uh cimetidine is uh drug drug interactions, and then um there's uh netizidine, which is a little harder to find. So most people are getting Fomotidine. Now, at this stage, if you're giving somebody H1, H2 blocker and they get worse, so they take phomodidine and they get sleepy and um foggy.
SPEAKER_02That's because of chemicals in the pill, so excipients in the pill, and then that's where you have to work with your compounding pharmacists to try them on a different uh packaging material, so like rice flour, uh as opposed to um micro uh mycocrystallate stearate. So uh that's an important thing to recognize. So if they're doing the wrong thing, unexpected, think about excipients, and then after that, there's what I call step one therapy, which is vitamin C, vitamin D, a nutraceutical, which is either um chrome sorry, quercetin, or leodolin, and then low-dose maltrexone.
SPEAKER_02So um basically five over-the-counter products and one uh product uh LDN. Why do I pick LDN? LDN uh will block um the chemicals uh receptors on the mast cell by uh giving 70 low dose naltrexone, you'll uh amplify production of endorphins, and endorphins reduce T and B cell and mast cell activation, and so it reduces inflammation.
SPEAKER_02And anytime there's excess inflammation, mast cells get more activated. And um, the other thing which I like is especially with the frequency of uh painful tender joints that we see in Ellers Danlow syndrome, you can get people that get improvement in their pain.
SPEAKER_00Yeah, yeah. So when we look at low dose and outrexon, let's talk about this one just a little bit more. There's a lot of individuals who don't respond well to it or they find they have to go to really low doses. Um, you know, just talk about briefly about your clinical observations because in like the natural health community, you know, when people are using it for autoimmunity without MCAST, they'll often start like two, two and a half milligrams, you know, and then quickly work something up to a four to five range.
SPEAKER_00But a lot of people in MCAST, like you cannot start them at that two, two and a half range.
SPEAKER_02Right. So if you look at Norman Marcus, now trexone, Norman Marcus Naltrexone, he came out with a uh paper last year looking at his patients with LR Danlos, and he decided to try going micro dose and slow increase because he thought some of the patients had too many side effects in the beginning, and that when he reduced it to super low doses, they did better. And so he did a case series of patients where he started with 0.1 and increased it every other day to get slowly increase it and um ultimately getting to what the patient needed.
SPEAKER_02So some of the patients needed 1.2, 0.7, and so forth. And in fact, I believe it was 1.2 was the average dose that patients with EDS, many of whom have MCAS, got to, and they did better. And in more, they actually got worse. And my uh former life as LDN prescribers was always to give one milligram and then go up every seven days by one milligram to get to 4.5.
SPEAKER_02But this study uh made me change my mind, and um, so I'm doing it slower. Um, it can take three months to get up to uh 4.5, and sometimes uh I will increase it faster depending on the patient. But if you look at the uh patients who are treated for Crohn's disease, there was a 15% dropout with the 4.5. So when they started 4.5, there were 15% just dropped out, and that's just in quote, normal people.
SPEAKER_02But you put in the sensitive people, the MCAS patients, you're gonna expect a much higher side effect profile with sudden onset of uh 4.5.
SPEAKER_00Yeah, and I think the takeaway on some of this is the right medication, you may have it, but it may not be prescribed at the dose that you can best tolerate. The other thing that you said about Fomodidine was very interesting was maybe if it's making you sleepy, once again, you've got to get it compounded. So once again, it's not necessarily the Fomodidine chemical, it's some of the other stuff involved with it. Because oftentimes, you know, like I'll have some patients, like, let's use hormones as an example.
SPEAKER_00They're like, oh, but I, you know, that caused me to flare. I'm like, well, did the hormone cause you to flare, or did the route of administration cause you to flare and some of the other stuff involved? Because it's it's not universal that this in itself does it. I find a lot of stuff that it's very dependent on the route of administration and almost more of a building up a tolerance to the medication in a way that's healthy for your system.
SPEAKER_02Well said. And then as far as being allergic to phomodidine and going the compounded route, I've had two patients out of hundreds who are actually allergic to phomodidine, the actual chemical. So you can't, you know, rule out everything.
SPEAKER_00Yeah. And you know, there's y'all did a great job of the 2026, you know, put together a little graphic of hey, here's common medications, here's different nutraceuticals that could be used. Um, put in other things beyond that. What you know, this may be speculative, but where are we going in the treatment space with this? Is there any type of you know, new things you're seeing clinically that you know you're applying and are seeing decent results with?
SPEAKER_02Yes. Uh, well, uh, low-dose GLP uh therapy has been amazing for some individuals. Um, I'll just give you an example. Uh, one patient who came to see me um after suffering for years, um, 12 years of being bedbound and bathroom bound because of diarrhea. She came to see me, and over the course of the year, I gave her, I think it was 10 different medications to try to see what would work for her.
SPEAKER_02And then finally, uh some of us were talking about the anti-inflammatory effects of GLP1 therapy, and I started giving uh it to this patient, and she got better for the first time, and then um she went from uh half a milligram uh of the YGovey on up stepwise to eight milligrams and was totally well, and uh she was in tears, in part because this is the best she had felt in 12 years, and she had to quit her job, she had to be uh suffering as uh a mother who really couldn't take care of her kids but wanted to, and um it is traumatic.
SPEAKER_02We tried to get one of the companies um to do a study, um uh, but they didn't want to do it with MCAS because MCAS is a tough one to study. There's so many different symptoms, and um there's a different profile, what we call phenotype, like it's like fibromyalgia for some patients where they have muscle tenderness, which is one of the top 12 uh symptoms, and um it's it's tough.
SPEAKER_02So um I tried to actually get them to think back could they do one for fibromyalgia? And this is a drug company that actually has a drug for fibromyalgia that was FDA approved many years ago, but they didn't want to do it, you know. So they have um issues about treating MCAS, fibro, and it's unfortunate. Uh, there is um a study that's being um talked about um doing irritable bowel syndrome uh therapy, and I'm talking with um one of the directors uh on the second of this month, and um so that could be exciting too, uh, and being an investigator with IBS because a lot of IBS is MCAS in disguise.
SPEAKER_00Yeah, and I've seen a lot of good results as well with the GLPs and a lot of people, you know, it's kind of a shame that it's been lumped into just the weight loss side versus look, we have to understand this thing impacts mast cells, it impacts insulin blood sugar, inflammation, like neurologically, like there's a lot of different ways that this can help people, and it's not about just raising people to a highest dose for max weight weight loss, like some people do beautifully on an entry-level dose, and they're like, What the like I was not expecting this to have this type of response for me, and then it can make something else be able to help them move the needle in a big way, and so I hope we can get more research on stuff like that because it it is helping.
SPEAKER_00And yes, there are a lot of different phenotypes, um, you know, even though none of them are classified, because as we said initially, right, we're looking at two systems of the body and and symptoms, you know. So you could have neurological, cardiovascular, pulmonary, you could have dermatological, you can have, you know, a big list. And I think part of that brings us to the next question is what can make mCAS difficult to treat?
SPEAKER_02Okay, so um number one, the mast cells live in tissues for a long time. So the uh muted mutated mast cells live in the tissues for a long time. They could live in fat for a long time and not um be readily uh oh, basically touched by the treatments that we're giving them because they're in the fat cells.
SPEAKER_02So they could be uh releasing their chemicals in fat, which then leads leaves the system to circulate, but we can't get to them uh because uh with meds, because they're in fat. So that's been shown uh in mice models uh adipose tissue, white adipose tissue uh being a site for uh inflammation from mast cells. Uh then there's the um prolonged uh release of the chemicals, which we talked about, and then that brings in other mast cells which go into the site where the um inflammation is, and then because they're uh disordered, uh the function of these mutated mast cells are disordered, they don't know when to shut off and stop activating.
SPEAKER_02Um, and then we have more and more um uh mutations that occur from let's say COVID or mono or other viruses, and then that's a problem. So yet more trouble. And because of all these receptors, uh you can't treat with one drug, you have to treat with multiple drugs. And um, our mast cell study that we published in 2025, where we looked at the GLP1.
SPEAKER_02Therapy in 47 patients. These patients were on an average of 13 medications. Well, they've been they were treated with up to 13 um drugs. And then we started the GLP1 and they improved. But the the fact is is that they're uh difficult to treat. And then you stumble upon GLP1, and uh they can get a lot better.
SPEAKER_02Constipation, though, and nausea are uh very common in the patients.
SPEAKER_00Yep, yeah, constipation, nausea, and that brings us back to GLP because you know one of the side effects of the GLP is nausea and constipation. So a lot of patients are confused, like, wait, this is better, but I thought this was a side effect. It's like, well, it can be, but it is, especially at a higher dose. But when you're quieting down your mast cells, you're actually getting the benefits. It's the same thing we've seen, people who've got POTS plus MCAS, and they're like, Whoa, the GLP has actually quieted down my POTS response.
SPEAKER_00It's like, well, yes, because you don't have as much inflammation, completely disrupting your autonomic nerve system's ability to function.
SPEAKER_02Right. Right. And that's uh um about 60% of patients will get better with POTS utilizing mast cell therapy. And that's because we know that uh the mast cells live in the sympathetic nervous system, um, and that when they release their chemicals, uh, the nerves are affected directly or indirectly. So, you know, hopefully uh people will be trying, more neurologic neurologists or cardiologists will try mast cell therapy because uh the fact is that 17 symptoms of POTS are shared by 17 symptoms of MCAS.
SPEAKER_02And both uh syndromes have you know 40 to 50 possible symptoms.
SPEAKER_00And that's something everyone needs to take away is one, there's considerable overlap, and next, most people are viewing histamine and mast cell from the old dermatologic perspective of hives, rashes, flushing versus hey, remember, you've got mast cells all over your blood brain barrier. Like any neurovascular bundle, there's an abundance of them. And as y'all said in the paper, and we haven't talked about it much. It's mast cells are one of the very first things that responds to an insult.
SPEAKER_00So it doesn't matter if it's an infection, it doesn't matter if it's a concussion, any type of insult, you you it your body doesn't know the difference of an insult. It just says, boom, there's an insult. We've got to do an initial immune response. So mast cells get activated, they are gonna release cause overriding mediators to try to get a job done. And the problem with mast cells that isn't talked about as much, is mast cells are a super important part of your immune response. The problem is with anything in the immune system, it's you know, the old saying, too much of a good thing can become a bad thing.
SPEAKER_00And that's the issue, is when it keeps going and it not only perpetuates itself because mast cells can do that, but it can perpetuate other immune cells to create more chaos.
SPEAKER_02I I enjoyed uh talking to you before we started about your experience with traumatic brain injury, uh, because uh when you look at the young gals who um are playing uh soccer and get um hit on their head, some with concussion, some not, but some their disease activates then, their MKS activates then, as well as when uh they go into uh puberty and um and then the estrogen is a strong stimulant to mast cells.
SPEAKER_02But uh the combination is uh I think something that we don't appreciate or tell the patients about enough, and um and I think that uh some of the symptoms are are treatable uh with mast cell therapy for both the um TBI in the setting of TBI alone or TBI with MCAS? Would you agree?
SPEAKER_00I would agree, and I always, you know, before I even knew about MCAS, I was screening people for it without knowing I was screening them for it. Because the way I was taught was if you really love the brain, you have to understand what makes the brain basically succeed or fail. So, like what happens to their neurological symptoms based upon what they eat, based upon chemical or environmental toxin exposures, based upon you know, allergies. For I've always asked people, hey, when you have allergies, do you just have like sinus issues or do you have way more brain fog?
SPEAKER_00Do you get dizzy? Does your light and noise sensitivity change? And I didn't realize I was actually screening them for MCAS versus, you know, I'm just like, I just know the immune system's important. When the immune system's off, it can wreck the brain. So I've got that I have to deal with, but I hadn't given it an official name.
SPEAKER_02And screening for things, I mean, we don't have enough time when we see a patient, you know, if you're seeing a new patient in 20 minutes or 30 minutes, there's not enough time to screen for everything. Now, I use the screening uh questionnaire, which I think is great, um, that based on Dr. Muldering's uh work in 20 years ago. But, you know, when I was, quote, a plain old gastroenterologist interested in checking for irritable bowel or uh Crohn's disease or polyps, you know, the review of systems was an afterthought.
SPEAKER_02Um, I it was hard to make it through and add it to my time, and nobody really did it. But if you want to help patients, you've got to look for what I call a bold review of systems. So on the computer, um, when they uh click out the uh electronic review of systems and past medical history, uh, then the patient uh denies symptom X and that symptom that system and symptom stays uh light color or fatigue and that becomes bold.
SPEAKER_02And then if you look just at their list of um review of systems, you see many, many positives that are bold, and so that's what I call a bold uh review of systems, and then you say, well, something could be going on now, and uh often you'll then get into a better discussion, and that's you know, actually concentrates more on review of systems where their heart's involved or their lungs are involved, you know.
SPEAKER_02So that's something that was a wake-up call for me.
SPEAKER_00Yeah, because at the end of the day, you know, whenever we look at MCAS, Ellers, Danlow syndrome, POTS, you know, these are all considered heterogeneous issues. And one of the parts that I loved from Consensus 2 was this just one small little part of it, but practitioners serve human needs first and science second. I was like, thank you so much, because I feel like that's what I've done because I started in the concussion and brain injury space whenever there was no treatment.
SPEAKER_00You literally just went and waited it out, and we're like, man, do we really just tell patients the same thing everyone else is telling them? Or is there some sort of mechanistic thing that we can take from the research and then start applying it clinically as long as we can do it safe? And and that's something y'all said in there as well. It's like, look, if we can give them something that we know is pretty safe, it's okay that we don't have the research yet that says, hey, go and do this, because as y'all stated in the article, I mean, it can take 20 to 40 years to get the research out.
SPEAKER_00And to tell a patient, sorry, you've got to wait that long. And it's why I actually have some other podcasts lined up with other authors of different articles where they basically are begging clinicians, because they're just researchers, they're like, please, like evaluate them from a more complete picture and then apply it. Like, please do it. Like, we don't have time to get individual evidence for every single one of these. It's up to you to take the research and bring it to your patient and apply it without being told, please act.
SPEAKER_00So, how do individuals find these types of providers? That's the challenging part.
SPEAKER_02It is challenging. Um, there's a group, um EDS Clinic Clinic, EDS Dot Clinic, EDS dot clinic, and they do uh telemedicine, uh, and they're they decided to not do MCAS dot clinic, just wanting to see how things worked. And I was pretty impressed uh with the group. I've met them um a lot of not a lot, but there are some doctors that do um telemedicine.
SPEAKER_02Some of them you need to go and see them, you know, whether it's in uh Phoenix or in Colorado. Um and uh I think there are a number of people who prescribe low-dose naltrexone that would be more likely than not to have read something about MCAS. So the LDN research. Sorry, LDN Trust.org could be helpful.
SPEAKER_02Ldn uh science.org is another one in terms of who prescribes LDN both nationally and in your state. And then um the integrative or functional doctors can be good. Now many of them are too uh wrapped up in endocrinology and do you know numerous um tests, uh testing of thyroid, and that's all there is, you know, but um many of them are more open-minded and have started going to the um A4M and other uh uh meetings that usually will have some education on MCAS.
SPEAKER_02Um I would love for them for this to be taught in med school, and we did have one med school UC, Irvine, um, now develop a uh curriculum that includes MCAS and uh POTS. And so in the future, when the um granddaughter of a dean sees how bad his daughter granddaughter is taken care of by doctors, then he's gonna say, What's going on, guys?
SPEAKER_02You need to wake up and get people taught how to take care of patients like my granddaughter. It's really I think that I think that's gonna be the biggest change. Things just don't happen fast in medicine.
SPEAKER_00No, that's spot on, because even a lot of the you know, physicians I know who've switched over to more functional medicine, that's why they switched. They switched because a loved one or themselves couldn't get answers in the system. And they realize, like, wow, you know, this is not helping us. And one of the last guests I had, you know, they've kind of taken a different approach. And I think you're head, you're basically heading there as well.
SPEAKER_00And I call it base when the specialist becomes more of a generalist. Like, you're like, holy smokes! Like, I realize the more I just lock in on this area, like everyone else, the more I'm just missing so many things that could benefit from these people. Not only am I missing it, but I'm ignoring the fact at how one system drives the other. You know, like, hey, you can have dietary stuff that drives migraines, versus saying, hey, I'm a neurologist, I could care less what you eat. Like, that's not my issue.
SPEAKER_00It's like, no, actually, it is, it impacts the brain. So we've got to get that into medicine. And I just don't know how, like you said, until the right person has the struggle and it hurts them to that level because it can't happen in short visits, like, even if they wanted to. How do you screen people on diet, sleep, exercise, stress, toxin exposure? Like, you can't.
SPEAKER_00It doesn't matter how good you are in a 10 and 20-minute visit.
SPEAKER_02Right, right. And then uh, but you're the people who go out and there's specialists, the cardiologists, endocrinologists, they're all living in their silo. So they don't allow themselves to go out of that silo to start thinking about well, how can you know uh migraines relate to my patients? Um, but in fact, if you look at their joints and you ask them, hey, are you double-jointed at the beginning of the conversation?
SPEAKER_02They say yes, and then you could play with their hands and uh and then show that they are hypermobile. Well, the fact is, if you look at those patients and migraine is your specialty, you can find an article that shows that those with LOS damelose have A, um, more migraines or B more um abdominal pain and GI symptoms. So those are the uh so then we could start lumping together. And then the thing that I say to um doctors is that don't get down to where you can't see the forest through the trees.
SPEAKER_02Look, listen to this worst symptoms, look at the um questionnaire, and those questionnaires available, which I'm happy to share with you. Um look at those questionnaires, look at the point value, um, and say, hey, okay, maybe this is MKS. If I can't do the um blood work or urine work because of uh uh unavailability, you could even try H1H2 blocker um and just mast cell stabilizers, which are over the counter.
SPEAKER_02Um you can try um chromalin, um, which I reserve uh to after naltrixone because of the expense, but you have to start it slowly. And then um I avoid in general singular unless they've got a lot of um uh pelvic floor uh pain, interstitial cystitis, um, severe uh allergies, because you have to warn them that there's risk of um mood disturbances uh including uh depression and anxiety.
SPEAKER_02And then right after that, um I go to a compounding pharmacy um to give them uh low dose um GLP1 starting at 0.25. So that's kind of how I get going. Okay, and then diet is very important, as you said. Uh probably in 30 to 40 percent people have problems with one of three gluten-free, dairy-free, and histamine free, um, as uh means towards getting them better.
SPEAKER_00And I just tell everyone to go gluten-free and dairy-free. I'm just like, look, trial it for a month. I'm like, if if after a month, maybe two months, you're like, look, it's not doing anything for me, fine, we'll we'll have that conversation. But I think it's silly to put people in big programs, to set them up on all these medications without ever even having a nutritional conversation. You know, if I think back to my wife's story, it's you know, multiple concussions, dysautonomia, um, you know, not sure if she had orthocyctic hypotension or POTS, right?
SPEAKER_00She was just told to eat a lot of potato chips and stuff to keep her salt levels good. Um she got rid of gluten, her brain fog improves by like 65%, headaches improve, right? Has to remove laundry detergent, dryer sheets, have to get all that cleaned up. I'm just like it's like I swear, you have like everything I treat, but you know, it's only in like looking in the looking back because I was in the concussion world first, so it was easier for me to see the concussions she had that were never diagnosed or treated from car accidents.
SPEAKER_02That was pretty apparent based upon her history, but then the other stuff is like oh amazing that just because you learned what you learned, you could apply that. Um, and I and it's a lucky thing, and I could say the same thing about my 10-year-old grandchild who uh for uh a year was severely affected by MCAS and and symptoms, neuropsychic problems before that, which needed to be addressed, but um weren't.
SPEAKER_02And you know, by the time that I saw Max and there was bruising, easy bruising and itching, and uh weight loss because of nausea and change of bowel habits, um, that I said, okay, we gotta get MCAS ruled out, and it was ruled in with the biopsies and the chromogranin elevation, and then minor uh OTC and naltrexone uh treatments worked, and um uh meds uh I mean dietary changes did not um need to be done so in max.
SPEAKER_02So uh, but a lot should be done to see what uh is a factor because that'd be nice, just changing the diet uh can help so many.
SPEAKER_00Yeah, and I tell people like even if it doesn't work for you and doesn't get you there, part of it is don't let it work against you. Like, hey, you're right, maybe getting rid of plug-in air fresheners doesn't get rid of it, but they're toxic, don't have it work against you, you know. Same thing with different detergents, same thing with makeup. Like, there's a lot of stuff that's super toxic to people, but it impacts everyone differently. So it's like just stack the deck in your favor.
SPEAKER_00Yeah, and you did, you know, you did recommend a website for those who like to learn more, triadlibrary.org. And one of the things that I think it says in there, or it says it in one of the other articles, is you know, with the triad, um just because it's uncommonly talked about and there's not a lot of awareness doesn't make it uncommon. So if people go there, you know, just briefly discuss what type of information they may be able to find to help them along the way.
SPEAKER_00So what what type of information you know is on the website that people could expect to find?
SPEAKER_02Uh let's see. Um so journal articles, um, and um if there's one great uh article um uh that you can modulate and change as a Word document if you're disabled. Um but um sources uh and education about meds and that kind of thing.
SPEAKER_00Okay. So if you know if you've got questions, you can absolutely go there because what most people need is just a little bit more clarity. There's so much confusion, there's so much noise out there, right? There's gaslighting, and then on the other side, it's you know, overselling of all sorts of stuff. And so being able to have things to look at that helps just bring a little bit of clarity is super important.
SPEAKER_02So I would also say that was the launching pad for our um drive to collect money for the um movie. So we did a documentary about uh the triad, and um uh it's produced and uh it can be seen. And so if um you have family or friends that need to understand what you've been going through, um understanding stealth syndromes on YouTube is a place to direct them.
SPEAKER_02It's just uh 59 minutes and can really help somebody because these patients, their their family um stops believing them, their friends stop believing them. Uh, it's really a um mind blower.
SPEAKER_00Yeah, but we'll be sure to share that with people so they can watch it because it's very true. You know, it's I always use uh orthopedic analogy for patients. I'm like, you know, it's always better to have a broken bone than a sprain. The broken bone's gonna heal come back completely fine. Sprain, you can have residual, but not only that, one shows up on an x-ray and the other one doesn't. So it's like, oh, see? Um and hopefully in the future that does change for this. And some of the ways that we can see what's happening gets more accepted.
SPEAKER_00Because I would argue there are things that we can see that are just not as accepted as well as other things are. Like if it's oh, it's colonoscopy, boom, it's there, right? People aren't gonna argue that as much. Um, imaging, oh, it's there, makes it easy. But hopefully in the future, there's more acceptance and awareness to this. And thank you for your time and bringing some awareness to this much important topic.
Post-exertional malaise is the hallmark feature of myalgic encephalomyelitis. It can occur for a variety of reasons, including infections such as COVID. While we are still trying to understand exactly what's driving...
Mast Cell Activation Syndrome, while still relatively unknown, is likely massively underdiagnosed. In this episode, I explore: What Mast Cell Activation Syndrome is The diagnostic criteria of Consensus 1 vs 2 Natural...
What happens when a physician develops long COVID and finds herself struggling to get the medical system to understand what she’s experiencing? In this episode of Brain Body Reset, I’m joined by internal medicine...
If you have POTS, you’ve probably heard conflicting explanations for your symptoms, each presented as the answer. How do you sort through the noise and figure out what actually applies to you? In this episode of Brain...
If you have POTS or another form of dysautonomia, you’ve probably been told to increase salt, push fluids, wear compression, and maybe try a medication or two. That advice isn’t wrong, but it’s compensation, not...